Year Founded
2022
Ownership
Private
Employees
~10
Stage
Preclinical
Modalities
Other

SOLID Therapeutics General Information

Developing first-in-class HCAR1 antagonists targeting both cancer cells and immune cells in solid tumors. High HCAR1 expression is associated with poor survival in breast and pancreatic cancer patients.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Copenhagen,
Denmark

Drug Pipeline

HCAR1 antagonist
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to SOLID Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

SOLID Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view SOLID Therapeutics's complete valuation and funding history, request access »

SOLID Therapeutics Investors

Innovation Fund Denmark
Investor Type: Venture Capital
Holding: Minority
Denmark’s Export and Investment Fund
Investor Type: Venture Capital
Holding: Minority
BioInnovation Institute Venture House Program
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »